CRDF Q2 2018 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q2 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$111,813+9.6% YoY

Gross Profit

-$92,623-82.8% margin

Operating Income

-$4M-3970.6% margin

Net Income

-$4M-3351.1% margin

EPS (Diluted)

$-3.03

QoQ Revenue Growth

+11.7%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$221,300

Balance Sheet

Total Assets

$22M

Total Liabilities

$4M

Stockholders' Equity

$17M

Cash & Equivalents

$18M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$111,813	$102,011	+9.6%
Gross Profit	-$92,623	-$236,192	+60.8%
Operating Income	-$4M	-$6M	+24.6%
Net Income	-$4M	-$8M	+53.4%